Needham Maintains Buy on RxSight, Lowers Price Target to $11

Benzinga Newsdesk www.benzinga.com Negative 68.9%

Neg 68.9% Neu 0% Pos 0%

Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $13 to $11.

Comments

No comments yet. Be the first!